Loss of exclusivity doesn’t mean the end of the income stream for branded drugs. Here’s how drug companies can mitigate the effects of drug patent expiration.
6 Ways to Maximize Product Value as Loss of Exclusivity Approaches Read Post »
This paper was originally published by Ingrid Freije, Stéphane Lamouche, and Mario Tanguay in Therapeutic Innovation & Regulatory Science under
Generic drug makers must tailor European market entry strategies to each country. Moreover, they must address the sequence in which they want to enter markets.
Generic Drug Market Entry in Europe: Why a Tailored Approach Is Best Read Post »
Get a free preview of Make Better Decisions Download the PDF Preview Get email updates Name Email HP Make Better
Drug patent expiration doesn’t always mean generics enter the market right away. Many factors affect generic drug launches and drug formulary changes.
Formulary Management and LCM Patent Strategies: A Complex Interaction Read Post »
There’s no reason to assume that every branded drug will fall victim to the “patent cliff.” Actions taken before drug patent expiration can extend drug life cycles.
5 Steps to Take When Your Drug Patent is About to Expire Read Post »
Artificial intelligence is allowing chemists to find new way to synthesize drug molecules, and forcing drug developers to shore up their patent strategies.
Will AI Help Challenge Drug Patents, or Strengthen Them? Read Post »
Recently a presentation by an Israeli patent examiner was brought forward in an argument against patent evergreening. In her presentation,
Does Drug Patent Evergreening Prevent Generic Entry? Read Post »
1. Introduction to the 505(b)(2) Pathway In the complex world of drug development and approval, the 505(b)(2) pathway stands out
Get fresh news and insights, drug patent expirations & more…
